



Published in final edited form as:

Nat Commun. ; 5: 4891. doi:10.1038/ncomms5891.

Streptomycin potency is dependent on MscL channel expression

Irene Iscla^{1,†}, Robin Wray^{1,†}, Shuguang Wei², Bruce Posner², and Paul Blount^{1,*}

¹Department of Physiology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390-9040, USA

²Department of Biochemistry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390-9038, USA

Abstract

The antibiotic streptomycin is widely used in the treatment of microbial infections. The primary mechanism of action is inhibition of translation by binding to the ribosome, but how it enters the bacterial cell is unclear. Early in the study of this antibiotic, a mysterious streptomycin-induced K⁺-efflux preceding any decrease in viability was observed; it was speculated that this changed the electrochemical gradient such that streptomycin better accessed the cytoplasm. Here we use a high throughput screen to search for compounds targeting the mechanosensitive channel of large conductance (MscL) and find dihydrostreptomycin among the “hits”. Furthermore, we find that MscL is not only necessary for the previously described streptomycin-induced K⁺-efflux, but also directly increases MscL activity in electrophysiological studies. The data suggest that gating MscL is a novel mode of action of dihydrostreptomycin, and that MscL’s large pore may provide a mechanism for cell entry.

Keywords

Streptomycin; antibiotic potency; MscL; aminoglycosides

Introduction

Streptomycin was the first antibiotic to be discovered in the aminoglycoside class and is derived from an actinobacterium of the *Streptomyces* genus¹. It is widely used in the treatment of serious bacterial infections caused by both gram-negative and gram-positive

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms

*Corresponding author: Dr Paul Blount, Department of Physiology, UTSW Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9040, USA, Tel: 214-645-6014, Paul.Blount@utsouthwestern.edu.

†These authors contributed equally to this publication.

Author Contributions II developed the HTS assay and performed the screen with the assistance, guidance and help of SW, and under the supervision of BP. RW performed the in vivo physiological and ion flux assays. II performed the electrophysiology, and PB initially conceived of and supervised the project. All authors contributed intellectually to the project and to the writing of the manuscript.

Competing financial interests

The authors declare no competing financial interests

bacteria including tuberculosis, endocardial and meningeal infections and the plague. Although it is known that the primary mechanism of action of streptomycin is through inhibition of protein synthesis by binding the ribosome, the mechanism of entry to the bacterial cell is not yet clear.

MscL is a highly conserved bacterial mechanosensitive channel that directly senses tension in the membrane². The physiological role of MscL is that of an emergency release valve that gates upon an acute drop in the osmolarity of the environment (hypoosmotic downshock)³. Under hypoosmotic stress, water enters the bacterial cell causing it to swell, thus increasing tension in the membrane; MscL gates in response to this tension forming a large pore of about 30Å⁴, thus allowing for the rapid release of solutes and saving the cell from lysis. Because of the large pore size, MscL gating is tightly regulated; expression of a mis-gating MscL channel, which opens at lower than normal tensions, causes slow bacterial growth or even cell death⁵.

Bacterial mechanosensitive channels have been proposed as ideal drug targets due to their important role in the physiology of bacteria and the lack of identified homologs in higher organisms⁶. We therefore performed a high throughput screen (HTS) searching for compounds that will inhibit bacterial growth in a MscL-dependent manner. Interestingly, among the hits we found four known antibiotics, among them the widely used aminoglycosides antibiotics streptomycin and spectinomycin.

Here we show that the potency of streptomycin is dependent on MscL expression in growth and viability experiments *in vivo*. We also provide evidence of the direct modulation of MscL channel activity by dihydrostreptomycin in patch clamp experiments *in vitro*. The involvement of MscL in the pathway of streptomycin action suggests not only a novel mechanism for how this bulky and highly polar molecule obtains access to the cell at low concentrations, but also new tools to modulate the potency of already known and potential antibiotics.

Results

HTS reveals MscL-dependent effect of known antibiotics

Under the hypothesis that MscL could serve as an antibiotic target, we performed a HTS of the UT Southwestern small molecule library (~230,000 compound) in search of MscL agonists, looking for compounds that would gate the channel and thus inhibit *Escherichia coli* (*E. coli*) bacterial growth in a MscL-dependent manner (see Methods for HTS details). Briefly, we used the *E. coli* MJF612 strain (Frag1 *mscL*, *mscS*, *mscK*, *ybdG*)⁷ expressing K55T *E. coli* MscL (K55T MscL), a mild gain-of-function mutant, and had bacterial growth as an output, measured as the optical density of the cultures at 595 nm (OD₅₉₅). Surprisingly, four known antibiotics were identified as potential candidates for MscL-specific decreased bacterial growth: dihydrostreptomycin, spectinomycin, viomycin and nifuroxazide. However, the primary mechanisms of action of these antibiotics are already known, with streptomycin, spectinomycin and viomycin affecting protein synthesis^{8, 9, 10} and nifuroxazide inhibiting dehydrogenase enzyme activity and causing DNA damage^{11, 12}.

Growth inhibition assays of these known antibiotics were performed using the same strain and mutant, K55T MscL, used in the original HTS⁵. For all four of the drugs, a concentration was easily found at which cells expressing K55T MscL, but not those containing empty plasmid, showed an antibiotic-dependent decreased growth. We then used this antibiotic concentration and assayed growth of the same cells expressing wild type (WT) Eco-MscL as well as MscL orthologs from the gram positive *Bacillus subtilis* (*B. subtilis*) and *Staphylococcus aureus* (*S. aureus*). An unrelated *E. coli* mechanosensitive channel that also detects membrane tension, MscS, was included to determine drug specificity for MscL. The results of these experiments are summarized in Figure 1. The aminoglycoside antibiotics dihydrostreptomycin and spectinomycin showed the clearest MscL dependence, affecting the growth of cells expressing all three MscL orthologs significantly more than the empty vector or MscS expressing cells. Viomycin also inhibited the growth of cells expressing the MscS channel and the orthologs but not the WT Eco MscL. Finally, although nifuroxazide had a milder effect on growth inhibition, it also showed a significant dependence on MscS as well as MscL channel expression. The observation that viomycin and nifuroxazide are MscS- and MscL-expression dependent in their potency suggests that they are non-specific activators of membrane tension-gated channels. They most likely work by intercalating into and adding tension within the cell plasma membrane, consistent with the finding that amphipaths, including lysophosphatidylcholine (LPC), could gate these channels^{13, 14}. On the other hand, the aminoglycoside antibiotics dihydrostreptomycin and spectinomycin appeared to be specifically MscL-dependent, and thus are likely to have direct influences on the MscL channel, with dihydrostreptomycin being the more potent. We therefore continued our analysis of dihydrostreptomycin, which seemed the most tractable system.

Streptomycin potency is MscL-dependent *in vivo*

A full concentration curve comparing growth inhibition by dihydrostreptomycin of cells expressing MscL or an empty plasmid clearly shows that MscL expressing cells are susceptible to lower concentrations of the antibiotic (Figure 2A). Furthermore, when comparing the effects of dihydrostreptomycin between a strain that expresses endogenous levels of MscL (MJF451) with another strain null for MscL (MJF455), we still observe a higher growth inhibition by streptomycin in the bacteria endogenously expressing MscL (Supplementary Fig. 1a). In order to verify that growth inhibition, measured as OD₆₀₀, reflected the changes in bacterial viability and not just altered bacteria cell shape or size, we performed viability experiments on agar plates containing different concentrations of dihydrostreptomycin. As shown in Figure 2B, at 3 or 4 μ M drug, viability of bacteria expressing WT and K55T MscL was one to three orders of magnitude lower than the viability of cells carrying empty vector or expressing the other major mechanosensitive channel, MscS; note that all cells showed decreased viability at higher concentrations of dihydrostreptomycin (Supplementary Fig.1b), consistent with the hypothesis that MscL increases potency, but is not the primary mechanism of action of the drug. These results are in good agreement with the observed MscL-dependent growth inhibition in liquid culture growth experiments (Figure 1), demonstrating that MscL expression increases bacterial susceptibility to dihydrostreptomycin.

Streptomycin induced K⁺ flux is MscL-dependent

Early studies trying to determine the mechanism of action of streptomycin indeed found that upon drug treatment a rapid flux of K⁺ out of the cell was observed prior to any decrease in viability¹⁵. Moreover, the same group describes a significant increase in streptomycin uptake if the bacteria are pre-diluted in a lower osmolarity media (hypo-osmotic shock) prior to streptomycin incubation¹⁶. Potassium is one of the major osmoprotectants, reaching several hundred mM in the cytoplasm, and can be fluxed by MscL from the cytoplasm in response to osmotic downshock^{17, 18}. Under the hypothesis that the observed K⁺-flux could be due to MscL activation by streptomycin, we compared the K⁺-flux induced by dihydrostreptomycin in bacterial cells with or without MscL expression. We measured the K⁺ remaining in the cells¹⁷, as well as viability, after different incubation times with dihydrostreptomycin. Briefly, cultures at approximately OD₆₀₀ = 0.2 were induced for 1 hour at 37°C degrees, then split in two: mock (no drug added) or with dihydrostreptomycin. The final OD₆₀₀ was taken and the amount of cells to be used was calculated, adjusting for OD. Approximately 1–1.5 ml of the cultures were then passed through a 0.45µm filter and washed, then dried as described in Methods. Three ml of double distilled water were added to each filter, and K⁺ levels were read using a flame photometer after a standard curve was established. Control values from four independent experiments were 131 ± 3 µM. As shown in Figure 3A, a K⁺-flux was observed after treatment of MscL-expressing bacteria; note that at 20 minutes there is a significant K⁺ flux, but no measurable decrease in viability (Figure 3A). No significant flux or decrease in viability was observed in cells not expressing MscL at this concentration of drug (Figure 3B). Note that the dihydrostreptomycin concentration used in these experiments (82µM) is higher than that used in the growth inhibition experiments because a higher osmolarity media was used for the cells to accumulate K⁺; as previously described higher streptomycin concentrations are needed to achieve the same effect in high osmolarity media¹⁹. Note that even at 40 minutes, little viability loss is noted in Figure 3B, where MscL is not expressed. We therefor tested this strain at a higher streptomycin concentration at which about a 50 % decrease in viability is observed at 40 minutes. However, even at this concentration, only modest streptomycin induced K⁺-flux is observed, and only after the decreases in viability occurred (Figure 3 C). These results strongly suggest that the streptomycin induced K⁺-flux is due to MscL activation.

Streptomycin also induces a MscL-dependent glutamate flux

When MscL gates, K⁺ is not the only molecule jettisoned from the cell, several osmolytes have also been proposed to go through this channel. One of these is glutamate²⁰, whose synthesis is increased upon exposure to high osmolarity^{21, 22}, and whose negative charge is thought to serve as a counter ion for K⁺. We therefore used the dihydrostreptomycin concentrations above and tested to see if glutamate was also fluxed from the cell in the 20 minute time scale in which K⁺ is seen to flux (see Figure 3A–C). Briefly, cultures at approximately OD₆₀₀ = 0.2 were induced for 1 hour at 37°C degrees, then split in two: mock (no drug added) or dihydrostreptomycin added. The final OD₆₀₀ of the cultures was recorded and 15 ml of each sample was pelleted, the supernatant removed and immediately frozen down to –80°C. Samples were re-suspended, adjusting volume for final OD₆₀₀. Glutamate measurements were performed as described in Methods, and control values from three independent experiments was 260 ± 20 µM. While there was no significant loss of

glutamate from cells not expressing MscL, 52% of the glutamate was lost from cells expressing it (Figure 4). Hence, it appears that streptomycin activation of MscL leads not only to the previously reported flux of K^+ prior to decreases in viability, but also leads to efflux of at least one other osmoprotectant: glutamate.

Streptomycin modulates MscL activity in patch clamp

Finally, we directly assessed the effects of these antibiotics on MscL channel activity in patch clamp. Briefly, we used the MJF612 strain expressing the K55T MscL mutant *in trans* to make the giant spheroplast preparation, which allows analysis within native bacterial membranes²³. We applied the drugs in the pipette, which reflects the periplasmic side of the channels, using the back-filled pipette method as previously performed²⁴ and described in the Methods section. This method allows for the assessment of channel activity within the same patch prior to and after drug exposure. As shown in Figure 3D, the presence of the antibiotics has significant effect in channel open probability (P_o treated /untreated 11.9 ± 3.7 ; $p < 0.002$, Student *t*-test dihydrostreptomycin vs. control unpaired $n = 3$, n being the number of independent patches before and after treatment). Consistently, a reduction in the pressure required to gate the channels was also observed (pressure threshold treated/untreated 0.85 ± 0.07 $p < 0.03$ Student *t*-test dihydrostreptomycin vs. control unpaired $n = 4$). No increases in P_o or reduction in pressure were observed in MscL untreated patches or in the activity of the unrelated mechanosensitive channel MscS (Supplementary Fig. 2). Similar increases in sensitivity of MscL mutants have previously been associated with potassium flux and slowed growth and decreases in viability⁵. The effects observed here on the channel sensitivity in patch clamp may be an underestimation due to the difference in membrane potential (~ -180 mV intact cell vs. -20 mV patch), given that dihydrostreptomycin is positively charged and a more negative membrane potential might favor interactions with the MscL channel at the membrane; note also that there is precedence for an increase in open probability at higher membrane potentials¹⁷. In sum, these experiments demonstrate that dihydrostreptomycin increases MscL channel activity.

Discussion

Here we present a novel mechanism for a known antibiotic: the specific activation of the mechanosensitive channel MscL. Although other studies have suggested that some compounds modulate MscL activity, specificity has never been demonstrated. For the bacterial toxin sublancin 168²⁵, a lantibiotic, a MscL-dependent viability of *B. subtilis* and *S. aureus* bacteria *in vivo* was observed, but no electrophysiological studies were performed, nor was there an assessment of the role MscS may play; hence, it is not clear if this lantibiotic acts directly or specifically with MscL. Another group of antimicrobial agents, parabens, as well as the spider toxin GsMTx4, have been reported to affect MscL as assayed by patch clamp, but no *in vivo* studies have determined any MscL-dependent effects for either class of compounds, and in patch experiments, they also influence MscS, suggesting that they work through an indirect mechanism involving the lipid membrane^{26, 27, 28}. Thus, there has previously been no compound shown to directly and specifically influences MscL gating.

Here we demonstrate that dihydrostreptomycin directly induces MscL activity, thus increasing the potency of the drug. In addition, this appears to be specific because, unlike viomycin and nifuroxazide, no difference in potency was observed upon MscS expression. We therefore propose a model for how MscL increases the potency of streptomycin that is consistent with previous findings as well as the data presented here (Figure 5). Initially, streptomycin interacts with MscL and activates it, thus leading to an outward flux of K^+ . The present data cannot exclude the possibility of streptomycin acting through another protein associated with the MscL channel, although no such interactions of MscL have ever been reported, thus a direct interaction would be the simplest data interpretation. This occurs within 20 minutes, but is not correlated with a detectable decrease in viability. According to early studies by Busse et al²⁹, the streptomycin induced K^+ flux does not lead to a decrease in the steep bacterial membrane potential (ca -165 mV), instead a slight hyperpolarization is observed. This hyperpolarization is not as great as one might expect if only K^+ was lost from the cell, so the authors speculated that anions may also flux from the cytoplasm. This finding is consistent with our results demonstrating a loss of glutamate as well as K^+ from the cell prior to any loss in viability. The slight hyperpolarization causes an enhanced electrochemical potential for the entrance to the cell of the positively charged streptomycin. Molecular sieving experiments have previously demonstrated that compounds up to 30\AA can go through the MscL pore⁴. While the resulting decrease in viability could be solely due the channel opening and the loss of solutes, streptomycin, about 10\AA in diameter, is well within this 30\AA size, making it likely that it would easily pass through the channel. Its positive charge would give it a large electrochemical gradient. Thus, the open MscL channel would be a pathway for streptomycin to enter the cell cytoplasm. Perhaps it is this enhanced transport through MscL that is solely responsible for the increase in potency that is observed. However, because streptomycin is still effective when MscL is not expressed, albeit requiring higher concentrations, there must also be alternative pathways to the cytoplasm. Regardless, the observation that spectinomycin also shows an increase in potency when MscL is expressed (Figure 1) demonstrates that this is not specific for streptomycin, but may be a mechanism common among aminoglycoside antibiotics. Given the finding that MscL activation increases drug potency and may increase the efficiency of a drug entering the bacterial cell, it seems likely that an agonist to MscL could be used as an adjuvant for other known or potential antibiotics to increase their efficacy.

Methods

Stains and cell Growth

Constructs were inserted in the pB10d expression vector^{5, 24, 30, 31} and the *E. coli* strain MJF612 (Frag1 *mscL::cm*, *mscS*, *mscK::kan*, *ybdG::apr*)⁷ was used as a host for all experiments. Unless stated otherwise, cells were grown in citrate-phosphate defined medium (CphM) consisting of (per liter: 8.57 g of Na_2HPO_4 , 0.87 g of K_2HPO_4 , 1.34 g of citric acid, 1.0 g of NH_4SO_4 , 0.001 g of thiamine, 0.1 g of $\text{Mg}_2\text{SO}_4 \cdot 7\text{H}_2\text{O}$, 0.002 g of $(\text{NH}_4)_2\text{SO}_4 \cdot \text{FeSO}_4 \cdot 6\text{H}_2\text{O}$) plus 1 mM ampicillin.

High Throughput Screen

We performed a very simple high throughput screen (HTS) with bacterial growth as an output measured as the optical density of the cultures at 595 nm (OD₅₉₅). We tested a total of ~230,000 compounds in the UT Southwestern institutional library and looked for compounds that inhibited bacterial growth (Z score < -3) Z score = (data point value-mean)/standard deviation. The *E. coli* strain MJF612 was used as a host for the K55T MscL mutant expressed in trans⁵ in pB10d expression vector. The positive control consisted of bacteria expressing the G26C MscL mutant in trans treated with 2mM MTSET⁺ (Toronto Research Chemicals, Toronto, ON, Canada), which opens MscL and causes severe growth inhibition^{32, 33}. This control was present in every assay plate (column 1). The assay had a Z-prime value > 0.75³⁴. Briefly, overnight cultures grown in CphM were diluted 1:200 in chilled (4°C) media and kept in ice until loading into plates. The assay was performed in clear 384 wells polystyrene plates with flat bottom, non-treated and sterile (Greiner Bio One, Monroe, NC, USA). Before loading the plates (75µl/well), cultures were induced with 1mM isopropyl β-D-1-thiogalactoside (IPTG) and cells expressing G26C MscL were treated with 2mM MTSET⁺. The compounds (dissolved in neat DMSO) were added to a 10µM final concentration to columns 3 to 22 of each assay plate, the lids were added, the plates were wrapped in foil and incubated for 14–16 hours in a shaker at 37°C, shaking at 110rpm. Plates were then read at 595nm. Our primary HTS consisted in a simple assay measuring the growth of bacteria using OD₅₉₅ as an output. In this series of experiments we used the *E. coli* strain MJF612 that lacks the four major mechanosensitive channels, expressing a very mild MscL mutant expressed in trans, K55T. This mutant was chosen because it is slightly more sensitive to pressure, has only a slightly retarded growth, is not located within the pore, and has similar channel kinetics to wild type (WT) MscL⁵. After normalization of absorbance values to the median of the DMSO controls (columns 2 and 23 of each 384 well assay plate) using GeneData's Screener™ analysis software (Assay Analyzer v.10), compounds that inhibited bacterial growth were selected (Z score < -3) with a final hit rate of just less than 1%. After filtering for redundancy, 1600 compounds were cherry-picked and retested in the primary assay at 10 µM in triplicate. These compounds were also tested in a similar secondary screen that measured the effect of the drugs in cells carrying empty plasmid. This secondary screen was used as a selectivity screen, so the positive hits that inhibited growth of these bacteria lacking MscL were discarded as non-specific.

Stationary growth experiments

E. coli strain MJF612 was used as a host for *E. coli* MscL (MscL), K55T *E. coli* MscL (K55T MscL), *Bacillus subtilis* MscL (Bsub MscL), *Staphylococcus aureus* MscL (Sau MscL) and *E. coli* MscS (MscS) constructs in the pB10d expression vector. Overnight cultures were grown in CphM plus 100µg ml⁻¹ ampicillin in a shaker incubator at 37°C and rotated at 250 cycles per min. The next morning cultures were diluted to 1:60 in the same media and grown for 30 minutes before inducing expression with 1mM IPTG. After 1 hour of induction all cultures were adjusted to an OD₆₀₀ of 0.1. The cultures were then diluted 1:3 into pre-warmed CphM plus 100µg ml⁻¹ ampicillin plus the antibiotic being tested. Cultures were loaded in 96 well plates (180µl/ well) in 7 replicates; plates were sealed with a breathable film for 96 well plates to avoid evaporation, wrapped in foil and incubated at 37°C for 16

hours without shaking. The OD₆₀₀ of the cultures was measured using a Multiskan Ascent (Thermo Scientific Inc., Waltham, MA, USA). The antibiotics were diluted to their final concentration from the following stock solutions: viomycin sulfate, (USP, Rockville MD) 5mM in H₂O; nifuroxazide (Sigma, St Louis, MO) 5mM in DMSO; dihydrostreptomycin (Sigma, St Louis, MO) and spectinomycin (Sigma, St Louis, MO) 50mM in H₂O.

Viability experiments

Cultures were started from single colonies and grown in Lennox Broth (LB) medium (Fisher Scientific, Pittsburgh, PA, USA) plus ampicillin (100 µg ml⁻¹). Overnight cultures were diluted 1:40 in the same media and grown to an OD₆₀₀ of 0.2. Cell lines with plasmids were then induced for 30 minutes to 1 hour with 1mM IPTG. After adjusting all cultures to an OD₆₀₀ 0.4, cultures were serially diluted from 10³ to 10⁶ in LB and liquid drops of 5µl of each dilution were placed on pre-warmed LB plates containing 1mM IPTG and either no drugs, or varying amounts of dihydrostreptomycin. Colonies forming units (CFU) were counted to determine cell viability. Typical values for the 100% values were 6 to 8 10⁷ CFUs.

Electrophysiology

E. coli giant spheroplasts were generated as previously described²³ from MJF612 strain expressing the K55T MscL mutant in trans. Patch clamp experiments were performed in the inside-out configuration, at room temperature under symmetrical conditions using a buffer consisting of 200 mM KCl, 90 mM MgCl₂, 10 mM CaCl₂, and 5 mM HEPES adjusted to pH 6.0. Patches were excised, and recordings were performed at 20 mV (for simplicity the patch traces openings are shown upward). Data were acquired at a sampling rate of 20 kHz with 10 kHz filtration using an AxoPatch 200B amplifier (Molecular Devices, Sunnyvale, CA, USA). A piezoelectric pressure transducer (World Precision Instruments, Sarasota, FL, USA) was used to measure the pressure throughout the experiments. Glass pipettes were backfilled with the antibiotic, with the tip containing patch buffer without the drugs. Traces taken right after the patch seal formation were used as controls for each experiment. Only patches that form seals within 3 minutes of back-filling the pipette were used and MscL response to pressure was measured immediately after forming the patch. Three consecutive measurements were taken for the control first time point, and MscL sensitivity within the patch was tested subsequently every 20 minutes.

Potassium flux experiments

The MJF612 strain was used for the K⁺ flux experiments¹⁷ either carrying an empty vector or expressing WT MscL. Overnight cultures were grown from a single colony in K10 media consisting of 46mM Na₂HPO₄, 23mM NaH₂PO₄, 8mM (NH₄)₂SO₄, 10mM KCl and 100mM NaCl, supplemented with 0.4 mM MgSO₄, 3 µM thiamine, 6 µM iron, 0.04% glucose plus 100µg ml⁻¹ ampicillin. The next morning cultures were diluted 1:50 in the same media; when they reached an OD₆₀₀ = 0.2 they were induced for 1 hour at 37°C degrees. The cultures were then split in two: mock no drug added and 82 µM or 140µM dihydrostreptomycin. The final OD₆₀₀ was taken and the amount of cells to be used was calculated, adjusting for OD. Typical OD values ranged from 0.47 to 0.67, and

approximately 1–1.5 ml of the cultures were then passed through a 0.45µm filter and washed with 3ml of K0 media (K10 with the KCl replaced by NaCl), of the same osmolarity and no supplements or ampicillin. The filters were placed in 100ml plastic beakers and then dried in an oven at 80 °C overnight covered with foil. The next morning 3 ml of double distilled water were added to each filter and K⁺ levels were read using a flame photometer after a standard curve was established. Typical values ranged from 90 to 140 mM, and about 50–70mM for the streptomycin treated bacteria expressing MscL.

Glutamate Assay

The MJF612 strain was used for the K⁺ flux experiments¹⁷ either carrying an empty vector or expressing WT MscL. Overnight cultures were grown from a single colony in K10 media consisting of 46mM Na₂HPO₄, 23mM NaH₂PO₄, 8mM (NH₄)₂SO₄, 10mM KCl and 100mM NaCl, supplemented with 0.4 mM MgSO₄, 3 µM thiamine, 6 µM iron, 0.04% glucose plus 100µg ml⁻¹ ampicillin. The next morning cultures were diluted 1:50 in the same media; when they reached an OD₆₀₀ = 0.2 they were induced for 1 hour at 37°C degrees. The cultures were then split in two: mock no drug added and 82 µM dihydrostreptomycin. The final OD₆₀₀ of the cultures was recorded and 15 ml of each sample was pelleted, the supernatant removed and immediately frozen down to –80°C. Samples were re-suspended in K0 media (no supplements) adjusting volume for final OD₆₀₀. Glutamate measurements were performed using the EnzyChrom™ Glutamate Assay Kit (BioAssay Systems Hayward, CA, USA) according to manufacturer's instructions.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors would like to thank Christina Eaton and Drs. Eric Hansen, Hannah Malcolm, Limin Yang, and Dalian Zhong for helpful discussions and critical reading of the manuscript. The work was supported by Grant I-1420 of the Welch Foundation, Grant RP100146 from the Cancer Prevention & Research Institute of Texas, and Grants AI08080701 and GM061028 from the National Institutes of Health. I.I. is supported by Grant 12SDG8740012 from the National American Heart Association. The HTS Core facility was supported by 1P01CA95471-09 (Dr. Steven McKnight) and 5P30 CA142543-03 (The Simmons Cancer Center, (Dr. James Willson). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

1. Waksman SA. Strain Specificity and Production of Antibiotic Substances. X. Characterization and Classification of Species within the Streptomyces Griseus Group. Proc Natl Acad Sci U S A. 1959; 45:1043–1047. [PubMed: 16590476]
2. Iscla I, Blount P. Sensing and responding to membrane tension: the bacterial MscL channel as a model system. Biophys J. 2012; 103:169–174. [PubMed: 22853893]
3. Levina N, Totemeyer S, Stokes NR, Louis P, Jones MA, Booth IR. Protection of *Escherichia coli* cells against extreme turgor by activation of MscS and MscL mechanosensitive channels: identification of genes required for MscS activity. EMBO J. 1999; 18:1730–1737. [PubMed: 10202137]

4. Cruickshank CC, Minchin RF, Le Dain AC, Martinac B. Estimation of the pore size of the large-conductance mechanosensitive ion channel of *Escherichia coli*. *Biophys J*. 1997; 73:1925–1931. [PubMed: 9336188]
5. Ou X, Blount P, Hoffman RJ, Kung C. One face of a transmembrane helix is crucial in mechanosensitive channel gating. *Proc Natl Acad Sci USA*. 1998; 95:11471–11475. [PubMed: 9736761]
6. Prole DL, Taylor CW. Identification and analysis of putative homologues of mechanosensitive channels in pathogenic protozoa. *PLoS One*. 2013; 8:e66068. [PubMed: 23785469]
7. Schumann U, Edwards MD, Rasmussen T, Bartlett W, van West P, Booth IR. YbdG in *Escherichia coli* is a threshold-setting mechanosensitive channel with MscM activity. *Proc Natl Acad Sci U S A*. 2010; 107:12664–12669. [PubMed: 20616037]
8. Ermolenko DN, Spiegel PC, Majumdar ZK, Hickerson RP, Clegg RM, Noller HF. The antibiotic viomycin traps the ribosome in an intermediate state of translocation. *Nat Struct Mol Biol*. 2007; 14:493–497. [PubMed: 17515906]
9. Woodcock J, Moazed D, Cannon M, Davies J, Noller HF. Interaction of antibiotics with A- and P-site-specific bases in 16S ribosomal RNA. *EMBO J*. 1991; 10:3099–3103. [PubMed: 1915283]
10. Moazed D, Noller HF. Interaction of antibiotics with functional sites in 16S ribosomal RNA. *Nature*. 1987; 327:389–394. [PubMed: 2953976]
11. Chamberlain RE. Chemotherapeutic properties of prominent nitrofurans. *J Antimicrob Chemother*. 1976; 2:325–336. [PubMed: 802123]
12. McCalla DR. Mutagenicity of nitrofurans derivatives. *Environmental Mutagenesis*. 1983; 5:745–765. [PubMed: 6311528]
13. Perozo E, Kloda A, Cortes DM, Martinac B. Physical principles underlying the transduction of bilayer deformation forces during mechanosensitive channel gating. *Nat Struct Biol*. 2002; 9:696–703. [PubMed: 12172537]
14. Martinac B, Adler J, Kung C. Mechanosensitive ion channels of *E. coli* activated by amphipaths. *Nature*. 1990; 348:261–263. [PubMed: 1700306]
15. Dubin DT, Hancock R, Davis BD. The sequence of some effects of streptomycin in *Escherichia coli*. *Biochimica et Biophysica Acta*. 1963; 74:476–489. [PubMed: 14071591]
16. Plotz PH, Dubin DT, Davis BD. Influence of salts on the uptake of streptomycin by *Escherichia coli*. *Nature*. 1961; 191:1324–1325. [PubMed: 14487240]
17. Blount P, Schroeder MJ, Kung C. Mutations in a bacterial mechanosensitive channel change the cellular response to osmotic stress. *J Biol Chem*. 1997; 272:32150–32157. [PubMed: 9405414]
18. Epstein W, Schultz SJ. Cation transport in *Escherichia coli*. *J Gen Physiol*. 1965; 49:221–234. [PubMed: 19873561]
19. Plunkett GE. Modified Degrees of Streptomycin Dependence and Resistance in *Escherichia Coli*. *J Gen Microbiol*. 1965; 38:189–195. [PubMed: 14287197]
20. Ajouz B, Berrier C, Garrigues A, Besnard M, Ghazi A. Release of thioredoxin via the mechanosensitive channel MscL during osmotic downshock of *Escherichia coli* cells. *J Biol Chem*. 1998; 273:26670–26674. [PubMed: 9756908]
21. Dinnbier U, Limpinsel E, Schmid R, Bakker EP. Transient accumulation of potassium glutamate and its replacement by trehalose during adaptation of growing cells of *Escherichia coli* K-12 to elevated sodium chloride concentrations. *Arch Microbiol*. 1988; 150:348–357. [PubMed: 3060036]
22. McLaggan D, Naprstek J, Buurman ET, Epstein W. Interdependence of K⁺ and glutamate accumulation during osmotic adaptation of *Escherichia coli*. *J Biol Chem*. 1994; 269:1911–1917. [PubMed: 7904996]
23. Blount P, Moe PC. Bacterial mechanosensitive channels: integrating physiology, structure and function. *Trends Microbiol*. 1999; 7:420–424. [PubMed: 10498951]
24. Blount P, Sukharev SI, Moe PC, Schroeder MJ, Guy HR, Kung C. Membrane topology and multimeric structure of a mechanosensitive channel protein of *Escherichia coli*. *EMBO J*. 1996; 15:4798–4805. [PubMed: 8890153]

25. Kouwen TR, Trip EN, Denham EL, Sibbald MJ, Dubois JY, van Dijl JM. The large mechanosensitive channel MscL determines bacterial susceptibility to the bacteriocin sublancin 168. *Antimicrob Agents Chemother.* 2009; 53:4702–4711. [PubMed: 19738010]
26. Kamaraju K, Sukharev S. The membrane lateral pressure-perturbing capacity of parabens and their effects on the mechanosensitive channel directly correlate with hydrophobicity. *Biochemistry.* 2008; 47:10540–10550. [PubMed: 18795793]
27. Nguyen T, Clare B, Guo W, Martinac B. The effects of parabens on the mechanosensitive channels of *E. coli*. *Eur Biophys J.* 2005; 34:389–395. [PubMed: 15770478]
28. Kamaraju K, Gottlieb PA, Sachs F, Sukharev S. Effects of GsMTx4 on bacterial mechanosensitive channels in inside-out patches from giant spheroplasts. *Biophys J.* 2010; 99:2870–2878. [PubMed: 21044584]
29. Busse HJ, Wostmann C, Bakker EP. The bactericidal action of streptomycin: membrane permeabilization caused by the insertion of mistranslated proteins into the cytoplasmic membrane of *Escherichia coli* and subsequent caging of the antibiotic inside the cells due to degradation of these proteins. *J Gen Microbiol.* 1992; 138:551–561. [PubMed: 1375623]
30. Blount P, Sukharev SI, Schroeder MJ, Nagle SK, Kung C. Single residue substitutions that change the gating properties of a mechanosensitive channel in *Escherichia coli*. *Proc Natl Acad Sci USA.* 1996; 93:11652–11657. [PubMed: 8876191]
31. Moe PC, Levin G, Blount P. Correlating a protein structure with function of a bacterial mechanosensitive channel. *J Biol Chem.* 2000; 275:31121–31127. [PubMed: 10846181]
32. Bartlett JL, Levin G, Blount P. An *in vivo* assay identifies changes in residue accessibility on mechanosensitive channel gating. *Proc Natl Acad Sci USA.* 2004; 101:10161–10165. [PubMed: 15226501]
33. Bartlett JL, Li Y, Blount P. Mechanosensitive channel gating transitions resolved by functional changes upon pore modification. *Biophys J.* 2006; 91:3684–3691. [PubMed: 16935962]
34. Zhang JH, Chung TD, Oldenburg KR. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. *J Biomol Screen.* 1999; 4:67–73. [PubMed: 10838414]




Figure 1. MscL-dependent inhibition of bacterial growth by known antibiotics agents
 Effects of antibiotics on the growth of bacteria hosting an empty vector (dark blue) or expressing *E. coli* MscS (orange), *E. coli* MscL (red), K55T MscL (green), *B. subtilis* (purple) and *S. aureus* MscL (light blue). The bars represent the growth of bacteria in the presence of 6.5 μ M dihydrostreptomycin, 100 μ M spectinomycin, 80 μ M viomycin or 7.5 μ M nifuroxazide, expressed as the percentage of the untreated sample ($(OD_{600}^{\text{treated}}/OD_{600}^{\text{untreated}}) * 100$). Error bars represent SEM (n = 4–5 independent experiments). *p < 0.0075, **p < 0.00005, Student *t*-test unpaired vs vector.




Figure 2. MscL-dependent susceptibility to dihydrostreptomycin

A Growth inhibition of liquid cultures of *E. coli* bacteria hosting an empty vector (dark blue) or expressing *E. coli* MscL (red) were grown at different dihydrostreptomycin concentrations. The data is expressed as the reduction in growth measured as OD (600) of the treated cultures compared to the untreated. Error bars reflect SEM ($n = 3-4$ independent experiments)

B The viability of bacteria carrying an empty vector (blue) or expressing *E. coli* MscL (red), *E. coli* MscS (orange), or K55T MscL (green) was measured in agar plates with different concentrations of dihydrostreptomycin. The number of viable colonies as a function of the antibiotic concentration is shown for one representative experiment.




Figure 3. Modulation of MscL channel activity by streptomycin

A The graph shows the percentage of potassium remaining in the a MscL null bacterial strain expressing *E. coli* MscL in trans (red solid line). Cell viability after 20 or 40 minutes of incubation with 82 μ M dihydrostreptomycin is also shown (red dotted line). Values are expressed as a percentage of values from the untreated cells. Error bars reflect SEM (n = 4 independent experiments)

B The graph shows the percentage of potassium remaining in a MscL null bacterial strain hosting the empty plasmid, pB10b, with no MscL insert (blue solid line). Cell viability after 20 or 40 minutes of incubation with 82 μ M dihydrostreptomycin is also shown (blue dotted line). Values are expressed as a percentage of values from the untreated cells. Error bars reflect SEM (n = 4 independent experiments)

C The graph shows the percentage of potassium remaining in a MscL null bacterial strain hosting the empty plasmid, pB10b, with no MscL insert (blue solid line), at a higher concentration of streptomycin where decreases in viability could be observed. Cell viability after 20 or 40 minutes of incubation with 140 μ M dihydrostreptomycin is also shown (blue dotted line). Values are expressed as a percentage of values from the untreated cells. Error bars reflect SEM (n = 4 independent experiments)

D Single channel recordings from patch clamp experiments in native bacterial membranes. The current traces show the activity of K55T MscL held at a potential of -20 mV and a

negative pressure of -190 mmHg, before and after treatment with $50\mu\text{M}$ dihydrostreptomycin.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 4. Streptomycin induces a MscL-dependent glutamate flux

A The flux of glutamate from *E. coli* bacteria expressing an empty vector or MscL was measured as the percentage of glutamate remaining in the bacterial cells after 20 minutes of incubation with 82 μ M dihydrostreptomycin. Error bars reflect SEM (n = 3 independent experiments).

B The viability of the bacterial cells was measured after the same treatment and is graph as a percentage viability of the untreated samples. Error bars reflect SEM. * p < 0.021, Student *t*-test treated vs. untreated paired, n=3.




Figure 5. Working model for streptomycin-MscL interactions

The model depicts the MscL channel in the lipid membrane, in a series of events starting on the left. A first interaction between streptomycin and the bacteria occurs, leading to the activation of MscL, which allows a K^+ -flux from the cell. This occurs prior to any decrease in viability. The open MscL pore could serve as a pathway for streptomycin into the cell cytoplasm. It is by this mechanism that MscL expression increases the potency of the drug.